Strata Oncology Announces Collaboration with the
National Cancer Institute to Identify Patients for the
NCI-MATCH Clinical Trial

Ann Arbor, Mich.  August 8, 2018

Strata Oncology Announces Collaboration with the
National Cancer Institute to Identify Patients for the
NCI-MATCH Clinical Trial

Ann Arbor, Mich.  August 8, 2018

Strata Oncology today announced a collaboration with the National Cancer Institute (NCI) for their precision medicine cancer trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131). The objective of this ongoing phase II trial, led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), is to match genetic abnormalities of tumors with suitable targeted therapy, regardless of cancer type. 

The StrataNGS™ test is utilized in routine clinical care across the Strata Precision Oncology Network (Network), a network of 11 leading health systems committed to advancing research and patient care through a clinical-research driven model for precision oncology. The comprehensive assay is available to all advanced solid tumor and lymphoma patients at no cost through the Strata Trial™, an observational protocol providing tumor molecular profiling and trial matching for 100,000 patients. Network members deploy a streamlined, data-driven precision medicine workflow that enables efficient identification of eligible patients, universal access to StrataNGS, and proactive enrollment on precision therapy trials. Through the collaboration with NCI, Strata Oncology and the Network will leverage this infrastructure to accelerate enrollment into MATCH treatment arms.

“The size and scope of NCI-MATCH provided inspiration for Strata’s highly-scaled, systematic approach to precision medicine clinical research,” said Dan Rhodes, PhD, CEO of Strata Oncology. “Universal access to tumor profiling paired with robust trial-matching is a core feature of Strata’s precision medicine platform, so we believe our health system partners are uniquely positioned to make a significant contribution to the success of this important study.”

About Strata Oncology

Strata Oncology is a precision medicine company dedicated to transforming cancer care by systematizing precision oncology across a network of health systems and pharma companies. We empower health systems to deliver a cost-effective, system-wide precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visit www.strataoncology.com

Strata Inquiries:
Strata Oncology Media Relations
734.527.1000
media@strataoncology.com